Did you mean 3,4 5r 3?
Displaying drugs 451 - 475 of 11963 in total
Reviparin
Reviparin is a low molecular weight heparin which seems to have a better safety profile than unfractionated heparin. It is prepared from porcine intestinal mucosa by nitrous acid depolymerization. Reviparin has a molecular weight of 3.9 kDa. It was developed by Abbott laboratories and in 2009, reviparin presented an orphan...
Approved
Investigational
Relugolix
Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name...
Approved
Investigational
Matched Iupac: … 1-(4-{1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo- ... 1H,2H,3H,4H-thieno[2,3-d]pyrimidin-6-yl}phenyl)-3-methoxyurea …
Rifaximin
Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of...
Approved
Investigational
Matched Products: … RIFAXIMINA 2% ... RIFAX 2% - POLVO PARA RECONSTITUIR SUSPENSIONORAL …
Fruquintinib
Fruquintinib is a novel small-molecule anti-VEGFR that targets VEGFR-1,-2, and -3 to inhibit angiogenesis. Tumor angiogenesis is one of the most critical biological processes for increasing oxygen and nutrient supply to cancer cells, and the VEGF/VEGFR pathway is one of the most critical pathways for this phenomenon.[A262102,A262107] Indeed, oncogenic activation,...
Approved
Investigational
Matched Iupac: … 6-[(6,7-dimethoxyquinazolin-4-yl)oxy]-N,2-dimethyl-1-benzofuran-3-carboxamide …
Matched Description: … Fruquintinib is a novel small-molecule anti-VEGFR that targets VEGFR-1,-2, and -3 to inhibit angiogenesis ... [A262097] There are 2 major approaches to combatting tumor angiogenesis: neutralization of VEGF/VEGFR ... This approval is based on favorable results obtained from the FRESCO and FRESCO-2 trials, where an increase …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Matched Description: … Fruquintinib is a novel small-molecule anti-VEGFR that targets VEGFR-1,-2, and -3 to inhibit angiogenesis ... [A262097] There are 2 major approaches to combatting tumor angiogenesis: neutralization of VEGF/VEGFR ... This approval is based on favorable results obtained from the FRESCO and FRESCO-2 trials, where an increase …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Rilmenidine
Rilmenidine has been used in trials studying the treatment of Hypertension and Chronic Kidney Disease.
Approved
Investigational
Matched Iupac: … N-(dicyclopropylmethyl)-4,5-dihydro-1,3-oxazol-2-amine …
Matched Categories: … Adrenergic alpha-2 Receptor Agonists …
Matched Categories: … Adrenergic alpha-2 Receptor Agonists …
Fezolinetant
Vasomotor symptoms (VMS), more colloquially known as hot flashes or night sweats, are some of the most common symptoms in menopause. With a median duration of 7.4 years, vasomotor symptoms are also the most common reasons why women seek treatments for menopausal issues.[A259591,A259596] Although mostly considered a nuisance, vasomotor symptoms...
Approved
Investigational
Matched Iupac: … 5-[(8R)-7-(4-fluorobenzoyl)-8-methyl-5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyrazin-3-yl]-3-methyl-1,2,4-thiadiazole …
Matched Categories: … Neurokinin 3 Receptor Antagonist …
Matched Categories: … Neurokinin 3 Receptor Antagonist …
Dalfampridine
Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
Approved
Levetiracetam
Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs).[L8606,L8600,L8615] Levetiracetam possesses a wide therapeutic index[L8615,A185918]...
Approved
Matched Iupac: … (2S)-2-(2-oxopyrrolidin-1-yl)butanamide …
Matched Products: … LEVETIRACETAM R. 100 MG/ML ... LEVETIRACETAM 100MG+3 NET ... LEVETIRACETAM 100MG+3 HORM …
Matched Products: … LEVETIRACETAM R. 100 MG/ML ... LEVETIRACETAM 100MG+3 NET ... LEVETIRACETAM 100MG+3 HORM …
Profenamine
Profenamine (also known as ethopropazine) is a medication derived from phenothiazine. It is primarily used as an antidyskinetic to treat Parkinsonism. It is sold under the trade name Parsitan in Canada. In the US, the marketing of profenamine has been discontinued.
Approved
Matched Synonyms: … 10-[2-(diethylamino)-2-methylethyl]phenothiazine ... 10-(2-diethylaminopropyl)phenothiazine ... 10-[2-(diethylamino)propyl]phenothiazine …
Matched Iupac: … diethyl[1-(10H-phenothiazin-10-yl)propan-2-yl]amine …
Matched Salts cas: … 1094-08-2 …
Matched Categories: … Heterocyclic Compounds, 3-Ring …
Matched Iupac: … diethyl[1-(10H-phenothiazin-10-yl)propan-2-yl]amine …
Matched Salts cas: … 1094-08-2 …
Matched Categories: … Heterocyclic Compounds, 3-Ring …
Latanoprostene bunod
Latanoprostene Bunod has been used in trials studying the treatment of Glaucoma, Ocular Hypertension, Open-Angle Glaucoma, Open Angle Glaucoma, and Intraocular Pressure.
As of November 2, 2017 the FDA approved Bausch + Lomb's Vyzulta (latanoprostene bunod opthalmic solution), 0.024% for the indication of reducing intraocular pressure in patients with open-angle...
Approved
Investigational
Matched Iupac: … 4-(nitrooxy)butyl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept ... -5-enoate …
Matched Description: … As of November 2, 2017 the FDA approved Bausch + Lomb's Vyzulta (latanoprostene bunod opthalmic solution …
Matched Description: … As of November 2, 2017 the FDA approved Bausch + Lomb's Vyzulta (latanoprostene bunod opthalmic solution …
Etacrynic acid
A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop...
Approved
Investigational
Matched Synonyms: … (2,3-Dichloro-4-(2-methylene-1-oxobutyl)phenoxy)acetic acid …
Matched Iupac: … 2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid …
Matched Iupac: … 2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid …
rhThrombin
rhThrombin (recombinant human thrombin) is being developed by ZymoGenetics, Inc. as a general aid to achieving hemostasis during surgery. ZymoGenetics is developing rhThrombin, a recombinant form of human thrombin that is not derived from animal or human blood, as an aid to controlling bleeding during surgery. Thrombin is used in...
Approved
Investigational
Reslizumab
Reslizumab is a humanized interleukin-5 (IL-5) antagonist monoclonal antibody (IgG4 kappa) that is produced by recombinant DNA technology in murine myeloma non-secreting 0 (NS0) cells. IL-5 is a pro-inflammatory cytokine that is responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils [FDA Label]. Elevated levels of eosinophils...
Approved
Investigational
Matched Description: … Reslizumab is a humanized interleukin-5 (IL-5) antagonist monoclonal antibody (IgG4 kappa) that is produced ... IL-5 is a pro-inflammatory cytokine that is responsible for the growth and differentiation, recruitment ... By targeting the IL-5 and disrupting its signalling pathways, reslizumab aims to inhibit eosinophil maturation …
Matched Categories: … Interleukin-5 Antagonist …
Matched Categories: … Interleukin-5 Antagonist …
Ritiometan
Ritiometan is a nasal spray which is marketed by the name Nécyrane in France. It is indicated for use in viral rhinitis/ the common cold.
Approved
Matched Iupac: … 2-({bis[(carboxymethyl)sulfanyl]methyl}sulfanyl)acetic acid …
Remdesivir
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase...
Approved
Investigational
Matched Iupac: … 2-ethylbutyl (2S)-2-{[(S)-{[(2R,3S,4R,5R)-5-{4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl}-5-cyano-3,4-dihydroxyoxolan ... -2-yl]methoxy}(phenoxy)phosphoryl]amino}propanoate …
Matched Description: … [L18438] Remdesivir was also approved by the European Commission on July 3, 2020. ... Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease ... Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase (RdRp) enzyme complex for …
Matched Categories: … Heterocyclic Compounds, 2-Ring ... SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor …
Matched Description: … [L18438] Remdesivir was also approved by the European Commission on July 3, 2020. ... Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease ... Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase (RdRp) enzyme complex for …
Matched Categories: … Heterocyclic Compounds, 2-Ring ... SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor …
Rufinamide
Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
Approved
Betamethasone phosphate
Betamethasone phosphate is a prodrug that is rapidly hydrolyzed, providing rapidly accessible betamethasone to agonize glucocorticoid receptors. Betamethasone provides greater anti-inflammatory activity than prednisolone with less sodium and water retention. Betamethasone sodium phosphate was granted FDA approval on 3 March 1965.
Approved
Vet approved
Matched Iupac: … ,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethoxy}phosphonic acid ... {2-[(1R,2S,3aS,3bS,9aS,9bR,10S,11aS)-9b-fluoro-1,10-dihydroxy-2,9a,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH …
Matched Description: … [L11994] Betamethasone sodium phosphate was granted FDA approval on 3 March 1965.[L11994] …
Matched Description: … [L11994] Betamethasone sodium phosphate was granted FDA approval on 3 March 1965.[L11994] …
Quercus stellata pollen
Quercus stellata pollen is the pollen of the Quercus stellata plant. Quercus stellata pollen is mainly used in allergenic testing.
Approved
Matched Mixtures name: … 3-oak Mix, Black/blackjack/post Pollen ... 5-oak Mix, Blackjack/bur/post/red/white Pollen …
Methysergide
An ergot derivative that is a congener of lysergic acid diethylamide. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize serotonin in the...
Approved
Matched Synonyms: … 1-Methyl-dextro-lysergic acid (+)-1-hydroxy-2-butylamide …
Matched Iupac: … (4R,7R)-N-(1-hydroxybutan-2-yl)-6,11-dimethyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1 …
Matched Categories: … Serotonin 5-HT2 Receptor Antagonists ... Serotonin 5-HT2A Receptor Antagonists ... Serotonin 5-HT2C Receptor Antagonists …
Matched Iupac: … (4R,7R)-N-(1-hydroxybutan-2-yl)-6,11-dimethyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1 …
Matched Categories: … Serotonin 5-HT2 Receptor Antagonists ... Serotonin 5-HT2A Receptor Antagonists ... Serotonin 5-HT2C Receptor Antagonists …
Regorafenib
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
Approved
Matched Iupac: … 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide …
Matched Salts cas: … 1019206-88-2 …
Matched Salts cas: … 1019206-88-2 …
Carglumic acid
Carglumic acid is a drug used for the treatment of hyperammonemia in patients with a deficiency in N-acetyl glutamate synthase. This rare genetic disorder results in elevated blood levels of ammonia, which can eventually cross the blood–brain barrier and cause neurologic problems, cerebral edema, coma, and death. Carglumic acid was...
Approved
Matched Synonyms: … (S)-2-ureidopentanedioic acid ... (2S)-2-(carbamoylamino)pentanedioic acid …
Matched Iupac: … (2S)-2-(carbamoylamino)pentanedioic acid …
Matched Products: … PERLUGA 200 MG DAĞILABİLİR TABLET, 5 ADET …
Matched Iupac: … (2S)-2-(carbamoylamino)pentanedioic acid …
Matched Products: … PERLUGA 200 MG DAĞILABİLİR TABLET, 5 ADET …
Quercus velutina pollen
Quercus velutina pollen is the pollen of the Quercus velutina plant. Quercus velutina pollen is mainly used in allergenic testing.
Approved
Matched Mixtures name: … 3-oak Mix, Black/blackjack/post Pollen …
Displaying drugs 451 - 475 of 11963 in total